Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

February 28, 2027

Conditions

Non-small Cell Lung Cancer(NSCLC)Head and Neck Squamous Cell Carcinoma(HNSCC)Renal Cell Carcinoma(RCC)Urothelial CarcinomaMalignant Melanoma

Interventions

DRUG

LB-LR1109

intravenous administration

Trial Locations (1)

RECRUITING

NEXT Oncology, Fairfax